KRAS and lung adenocarcinoma: Administration of SMAP therapy to activate PP2A in KRAS-driven lung adenocarcinoma mouse xenografts resulted in the inhibition of tumour growth, decreased phosphorylation of ERK and induction of apoptosis of cancer cells when compared to vehicle controls [184].